20% of some 7 million US patients with bipolar disorder commit suicide. US-Israeli company NRx is currently undergoing a US trial on 72 bipolar patients involving the simultaneous administering of two anti-depression treatments that do not have hallucinogenic side effects.

https://www.calcalistech.com/ctechnews/article/b1kv2lfwo

https://www.nrxpharma.com/nrx-100-nrx-101/